Intervention
CVN424 (GPR6 inverse agonist)
Indication
Parkinson's Disease (Motor Complications)
Enrollment
~400 participants (planned)
CVN424 is a novel non-dopaminergic drug candidate being developed by Cerevance for the treatment of Parkinson's disease motor complications. It is a highly selective inverse agonist of GPR6, a G-protein-coupled receptor highly expressed in striatal medium spiny neurons (MSNs) of the indirect pathway.
The Phase 3 ARISE trial (NCT06553027) is evaluating CVN424 as an adjunctive therapy for Parkinson's disease patients experiencing motor fluctuations (OFF time). This represents a fundamentally different approach from traditional dopamine agonists, potentially offering efficacy with reduced dopaminergic side effects.
Parkinson's disease affects approximately 10 million people worldwide and is characterized by the progressive loss of dopaminergic neurons in the substantia nigra. While dopaminergic therapies (levodopa, dopamine agonists) are effective initially, long-term use leads to motor complications including OFF episodes (periods when medication wears off and motor symptoms return) and dyskinesias (involuntary movements).
GPR6 is an orphan G-protein-coupled receptor with a unique distribution profile:
- Highly selective expression: GPR6 is expressed almost exclusively in striatal medium spiny neurons of the indirect pathway, with minimal expression elsewhere in the brain
- Indirect pathway localization: The indirect pathway modulates movement through the basal ganglia-thalamocortical circuit. Overactivity of this pathway contributes to bradykinesia and rigidity in PD
- Constitutive activity: GPR6 exhibits high constitutive (baseline) activity, meaning it is constitutively active even in the absence of an agonist
flowchart TD
A["CVN424"] --> B["GPR6 Inverse Agonism"]
click A "/therapeutics/cvn424" "CVN424"
click B "/genes/gpr6" "GPR6 Gene"
style A fill:#f3e5f5,stroke:#333
B --> C["Reduced Indirect Pathway Activity"]
style C fill:#c8e6c9,stroke:#333
C --> D["Normalization of Basal Ganglia Output"]
C --> E["Reduced Bradykinesia"]
style D fill:#c8e6c9,stroke:#333
style E fill:#c8e6c9,stroke:#333
D --> F["Improved Motor Function"]
E --> F
style F fill:#c8e6c9,stroke:#333
click F "/mechanisms/basal-ganglia-circuit" "Basal Ganglia"
G["Dopamine Loss in SNc"] --> H["Excessive Indirect Pathway Activity"]
H --> I["Parkinsonism"]
style G fill:#ffcdd2,stroke:#333
style H fill:#ffcdd2,stroke:#333
style I fill:#ffcdd2,stroke:#333
click G "/diseases/parkinsons-disease" "Parkinson's Disease"
J["Traditional Dopamine Agonists"] --> K["Direct Dopamine Receptor Activation"]
K --> L["Dopaminergic Side Effects"]
K --> M["OFF Time & Dyskinesias"]
style J fill:#fff3e0,stroke:#333
style L fill:#ffcdd2,stroke:#333
style M fill:#ffcdd2,stroke:#333
click K "/therapeutics/dopamine-agonists" "Dopamine Agonists"
F --> N["Non-dopaminergic Approach"]
style N fill:#f3e5f5,stroke:#333
N --> O["Reduced Side Effects"]
style O fill:#c8e6c9,stroke:#333
The GPR6 target offers several theoretical advantages over dopaminergic approaches:
- Anatomical precision: By targeting the indirect pathway specifically, CVN424 can modulate motor circuits without directly stimulating dopamine receptors
- Non-dopaminergic mechanism: Avoids the side effects associated with direct dopamine receptor activation, including:
- Psychosis and hallucinations
- Impulse control disorders
- Sleep attacks
- Peripheral edema
- OFF time reduction: Phase 2 data demonstrated significant reduction in OFF time while maintaining or improving ON time
- Dyskinesia potential: By avoiding direct dopamine receptor stimulation, may reduce the development of levodopa-induced dyskinesias
CVN424 was discovered using Cerevance's NETSseq (Nuclear Enriched Transcript Sequencing) platform, which allows for the identification of novel drug targets with highly specific expression patterns in the brain. This approach identified GPR6 as a target enriched in the indirect pathway neurons.
| Milestone |
Date |
| First-in-human dosing (Phase 1) |
September 2018 |
| Phase 2 trial initiated (ASCEND) |
December 2019 |
| Positive Phase 2 results |
March 2022 |
| Phase 2 ASCEND topline (AD/PD 2025) |
April 2025 |
| Phase 3 ARISE first patient dosed |
November 2024 |
| Expected Phase 3 topline data |
First half 2026 |
The Phase 2 ASCEND trial evaluated CVN424 as monotherapy for early-stage Parkinson's disease:
- OFF time reduction: 1.73 hours reduction in OFF time versus baseline (p<0.01)
- 45% improvement: 45% increase in OFF time efficacy compared to baseline
- Low dyskinesia rates: Significantly lower rates of dopaminergic side effects compared to standard treatments
- Well-tolerated: CVN424 demonstrated a favorable safety profile in Phase 2
- Reduced side effects: Up to 150% reduction in common side effects compared to current treatment options
- Low rates of: Impulse control disorders, hallucinations, and peripheral edema
The Phase 3 ARISE trial (NCT06553027) is a randomized, double-blind, placebo-controlled study:
| Parameter |
Details |
| Phase |
Phase 3 |
| Design |
Randomized, double-blind, placebo-controlled |
| Population |
Parkinson's disease with motor complications |
| Intervention |
CVN424 oral tablets |
| Primary Endpoint |
Change in OFF time from baseline |
| Secondary Endpoints |
ON time, UPDRS scores, dyskinesia scales |
Approximately 400 participants with Parkinson's disease experiencing motor fluctuations will be enrolled at multiple sites globally.
| Treatment |
Mechanism |
Efficacy (OFF reduction) |
Key Concerns |
| CVN424 (ARISE) |
GPR6 inverse agonist |
1.73 hrs (Phase 2) |
Novel mechanism |
| Pramipexole |
D3/D2 agonist |
1-2 hrs |
ICD, hallucinations |
| Rotigotine |
D3/D2 agonist |
1-2 hrs |
Skin reactions |
| Apomorphine |
D1/D2 agonist |
2-4 hrs |
Injection site reactions |
| Levodopa/carbidopa/entacapone |
COMT inhibitor |
0.5-1 hr |
Dyskinesias |
CVN424 represents a fundamentally different approach by targeting the indirect pathway directly rather than replacing dopamine, potentially offering efficacy with improved side effect profile.
Cerevance is a privately held pharmaceutical company focused on developing novel therapeutics for central nervous system disorders using their proprietary NETSseq platform. The company was founded with the goal of identifying brain-selective drug targets with improved therapeutic windows.
¶ Leadership and Funding
- Headquartered in Cambridge, Massachusetts
- Backed by leading life sciences investors
- Focused on Parkinson's disease, Alzheimer's disease, and other neurological conditions
- Basal Ganglia Circuit in Parkinson's Disease
- Parkinson's Disease OFF Time
- Indirect Pathway in Movement Control